Industry & Policy News

[Max Planck Florida Institute] The National Institute on Aging of the NIH has awarded Dr. Yingxue Wang $1,038,819 over three years as part of the Alzheimer’s Disease Initiative Fund.

[Roche] Roche announced that it was made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic NSCLC.

[Aegle Therapeutics Corp. (PR Newswire)] Aegle Therapeutics Corp. announced the first patient has been dosed in the Phase I/IIa clinical trial of AGLE-102™ for the treatment of severe second-degree burns.

[Tonix Pharmaceuticals Holding Corp.] Tonix Pharmaceuticals Holding Corp. announced that it received the official written response from a Type B pre-Investigational New Drug Application meeting with the US FDA to develop TNX-8011 as a potential vaccine to protect against mpox disease and smallpox.

[Fierce Pharma (Regeneron)] Regeneron has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited immune condition Chaple disease. The disease, which is also known as CD55-deficient protein-losing enteropathy, has a global patient population of fewer than 100 people.

[OncLive] The FDA granted an orphan drug designation to the IgG1k type murine monoclonal antibody MAb-AR20.5 for the treatment of patients with pancreatic cancer, according to an announcement from CanariaBio.